Analyst Moves: BIIB, GEVA |
January 03, 2013 | January 2013 Bond Updates |
Biogen Idec (BIIB) was downgraded by Piper Jaffray (PJC) to neutral from overweight, as the share price has been approaching the previously set $168 price target. |
View more at: http://www.forbes.com/sites/marketnewsvideo/2013/01/03/analyst-moves-biib-geva/ |
Related News |
|